VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Down 37.1% in November

VYNE Therapeutics Inc. (NASDAQ:VYNE) was the target of a significant decrease in short interest in November. As of November 30th, there was short interest totalling 64,300 shares, a decrease of 37.1% from the November 15th total of 102,200 shares. Based on an average trading volume of 81,800 shares, the short-interest ratio is currently 0.8 days. Approximately 0.5% of the company’s stock are short sold.

VYNE Therapeutics Stock Up 6.7 %

Shares of VYNE Therapeutics stock opened at $2.56 on Friday. The company has a market cap of $37.76 million, a PE ratio of -2.98 and a beta of 1.37. VYNE Therapeutics has a 52 week low of $1.57 and a 52 week high of $3.43. The business has a 50 day moving average price of $2.63 and a 200-day moving average price of $2.20.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. BTIG Research started coverage on VYNE Therapeutics in a report on Monday, November 18th. They set a “buy” rating and a $8.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $5.75 price target on shares of VYNE Therapeutics in a research note on Friday, November 8th.

Institutional Investors Weigh In On VYNE Therapeutics

An institutional investor recently bought a new position in VYNE Therapeutics stock. Lynx1 Capital Management LP purchased a new position in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics accounts for approximately 0.0% of Lynx1 Capital Management LP’s portfolio, making the stock its 17th biggest holding. Lynx1 Capital Management LP owned approximately 0.11% of VYNE Therapeutics as of its most recent SEC filing. Institutional investors own 83.78% of the company’s stock.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.